Flavian D. Brown

Flavian D. Brown has extensive experience in the field of immunology and therapeutics. Flavian D. has worked as a Principal Scientist at GV20 Therapeutics since 2023. Prior to that, they served as a Principal Scientist at Immunitas Therapeutics from 2021 to 2023, where they led the CD83 program and conducted IND-enabling studies for IMT-009. Flavian also worked as a Senior Scientist at Jnana Therapeutics from 2019 to 2021 and as a Scientist at Neon Therapeutics from 2018 to 2019. Before joining industry, they conducted postdoctoral research at the Dana-Farber Cancer Institute, investigating the immunostimulatory potential of lymph node fibroblastic reticular cells (FRCs). Flavian completed their Ph.D. in Immunology at Harvard University, where they studied the immunostimulatory potential of FRCs and the molecular basis for T cell sensitivity to FRC-mediated suppression. Flavian D. also worked as a post-baccalaureate research fellow at the Mayo Clinic, assessing the genetic and epigenetic contributions to multiple myeloma tumorigenesis, and as a research fellow at the Broad Institute of MIT and Harvard, studying activating K-Ras mutations in non-small-cell lung cancer.

Flavian D. Brown earned a Bachelor of Arts (B.A.) degree in Biology from Carleton College, which they attended from 2005 to 2009. Flavian D. then pursued a Doctor of Philosophy (Ph.D.) degree in Immunology at Harvard University, where they studied from 2010 to 2017. Additionally, Flavian had the opportunity to partake in a study abroad program at the University of Sussex in 2007.